Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long‐term survival

UDC.coleccionInvestigaciónes_ES
UDC.grupoInvInsuficiencia Cardíaca Avanzada e Transplante Cardíaco (INIBIC)es_ES
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruñaes_ES
UDC.issue2es_ES
UDC.journalTitleJournal of the American Heart Associationes_ES
UDC.startPagee019949es_ES
UDC.volume10es_ES
dc.contributor.authorBermejo, Javier
dc.contributor.authorGonzález‐Mansilla, Ana
dc.contributor.authorMombiela, Teresa
dc.contributor.authorFernández, Ana I.
dc.contributor.authorMartínez‐Legazpi, Pablo
dc.contributor.authorYotti, Raquel
dc.contributor.authorGarcía‐Orta, Rocío
dc.contributor.authorSánchez‐Fernández, Pedro L.
dc.contributor.authorCastaño, Mario
dc.contributor.authorSegovia Cubero, Javier
dc.contributor.authorEscribano, Pilar
dc.contributor.authorSan Román, J. Alberto
dc.contributor.authorBorrás, Xavier
dc.contributor.authorAlonso Gómez, Ángel María
dc.contributor.authorBotas, Javier
dc.contributor.authorCrespo-Leiro, María Generosa
dc.contributor.authorVelasco, Sonia
dc.contributor.authorBayes-Genis, A.
dc.contributor.authorLópez, Amador
dc.contributor.authorMuñoz-Aguilera, Roberto
dc.contributor.authorJiménez-Navarro, Manuel Francisco
dc.contributor.authorGonzález‐Juanatey, J.R.
dc.contributor.authorEvangelista, Arturo
dc.contributor.authorElízaga, Jaime
dc.contributor.authorMartín‐Moreiras, Javier
dc.contributor.authorGonzález‐Santos, José M.
dc.contributor.authorMoreno Escobar, Eduardo
dc.contributor.authorFernández-Avilés, Francisco
dc.date.accessioned2021-02-08T12:18:44Z
dc.date.available2021-02-08T12:18:44Z
dc.date.issued2021-01-19
dc.description.abstract[Abstract] Background. The determinants and consequences of pulmonary hypertension after successfully corrected valvular heart disease remain poorly understood. We aim to clarify the hemodynamic bases and risk factors for mortality in patients with this condition. Methods and Results. We analyzed long‐term follow‐up data of 222 patients with pulmonary hypertension and valvular heart disease successfully corrected at least 1 year before enrollment who had undergone comprehensive hemodynamic and imaging characterization as per the SIOVAC (Sildenafil for Improving Outcomes After Valvular Correction) clinical trial. Median (interquartile range) mean pulmonary pressure was 37 mm Hg (32–44 mm Hg) and pulmonary artery wedge pressure was 23 mm Hg (18–26 mm Hg). Most patients were classified either as having combined precapillary and postcapillary or isolated postcapillary pulmonary hypertension. After a median follow‐up of 4.5 years, 91 deaths accounted for 4.21 higher‐than‐expected mortality in the age‐matched population. Risk factors for mortality were male sex, older age, diabetes mellitus, World Health Organization functional class III and higher pulmonary vascular resistance—either measured by catheterization or approximated from ultrasound data. Higher pulmonary vascular resistance was related to diabetes mellitus and smaller residual aortic and mitral valve areas. In turn, the latter correlated with prosthetic nominal size. Six‐month changes in the composite clinical score and in the 6‐minute walk test distance were related to survival. Conclusions. Persistent valvular heart disease–pulmonary hypertension is an ominous disease that is almost universally associated with elevated pulmonary artery wedge pressure. Pulmonary vascular resistance is a major determinant of mortality in this condition and is related to diabetes mellitus and the residual effective area of the corrected valve. These findings have important implications for individualizing valve correction procedures.es_ES
dc.identifier.citationBermejo J, González-Mansilla A, Mombiela T, Fernández AI, Martínez-Legazpi P, Yotti R, García-Orta R, Sánchez-Fernández PL, Castaño M, Segovia-Cubero J, Escribano-Subias P, Alberto San Román J, Borrás X, Alonso-Gómez A, Botas J, Crespo-Leiro MG, Velasco S, Bayés-Genís A, López A, Muñoz-Aguilera R, Jiménez-Navarro M, González-Juanatey JR, Evangelista A, Elízaga J, Martín-Moreiras J, González-Santos JM, Moreno-Escobar E, Fernández-Avilés F; SIOVAC (“Sildenafil for Improving Outcomes after VAlvular Correction”) Investigators. Persistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long‐term survival. J Am Heart Assoc. 2021 Jan 19;10(2):e019949.es_ES
dc.identifier.issn2047-9980
dc.identifier.urihttp://hdl.handle.net/2183/27307
dc.language.isoenges_ES
dc.publisherWilleyes_ES
dc.relation.urihttps://doi.org/10.1161/JAHA.120.019949es_ES
dc.rightsCreative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC 4.0)es_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectHeart failurees_ES
dc.subjectPulmonary hypertensiones_ES
dc.subjectValvular heart diseasees_ES
dc.titlePersistent pulmonary hypertension in corrected valvular heart disease: hemodynamic insights and long‐term survivales_ES
dc.typejournal articlees_ES
dspace.entity.typePublication
relation.isAuthorOfPublication36d178fd-10a0-48a2-925d-71d185a50eda
relation.isAuthorOfPublication.latestForDiscovery36d178fd-10a0-48a2-925d-71d185a50eda

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
CrespoLeiro_2021_Persistent-Pulmonary_Hypertension_Corrected_Valvular_Heart_Disease.pdf
Size:
1.67 MB
Format:
Adobe Portable Document Format
Description: